Heart Failure Reviews最新文献_第3页

Noninvasive biometric monitoring technologies for patients with heart failure. 针对心力衰竭患者的无创生物识别监测技术。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-10-22 DOI: 10.1007/s10741-024-10441-7

Jose Arriola-Montenegro, Pornthira Mutirangura, Hassan Akram, Adamantios Tsangaris, Despoina Koukousaki, Michael Tschida, Joel Money, Marinos Kosmopoulos, Mikako Harata, Andrew Hughes, Andras Toth, Tamas Alexy

{"title":"Noninvasive biometric monitoring technologies for patients with heart failure.","authors":"Jose Arriola-Montenegro, Pornthira Mutirangura, Hassan Akram, Adamantios Tsangaris, Despoina Koukousaki, Michael Tschida, Joel Money, Marinos Kosmopoulos, Mikako Harata, Andrew Hughes, Andras Toth, Tamas Alexy","doi":"10.1007/s10741-024-10441-7","DOIUrl":"https://doi.org/10.1007/s10741-024-10441-7","url":null,"abstract":"Heart failure remains one of the leading causes of mortality and hospitalizations in the US that not only impacts quality of life but also poses a significant public health burden. The majority of affected patients are admitted with signs and symptoms of congestion. Despite the initial enthusiasm, traditional remote monitoring strategies focusing primarily on weight gain failed to improve clinical outcomes. Implantable pulmonary artery pressure sensors provide earlier and actionable data, but most patients would favor forgoing an invasive procedure in favor of an alternative, non-invasive monitoring platform. Several devices utilizing different combinations of multiparameter monitoring to reliably detect congestion have recently been developed and are undergoing testing in the clinical setting. Combining these sensors with the power of artificial intelligence and machine learning has the potential to revolutionize remote patient monitoring and early congestion detection and to facilitate timely interventions by the care team to prevent hospitalization. This manuscript provides an objective review of novel, noninvasive, multiparameter remote monitoring platforms that may be tailored to individual heart failure phenotypes, aiming to improve quality of life and survival.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dietary sodium intake restriction in patients with heart failure: an overview of systematic reviews. 心力衰竭患者的饮食钠摄入限制：系统综述。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-10-19 DOI: 10.1007/s10741-024-10452-4

Congying Liu, Yating Wang, Heli Zhang, Sumei Tong

{"title":"Dietary sodium intake restriction in patients with heart failure: an overview of systematic reviews.","authors":"Congying Liu, Yating Wang, Heli Zhang, Sumei Tong","doi":"10.1007/s10741-024-10452-4","DOIUrl":"https://doi.org/10.1007/s10741-024-10452-4","url":null,"abstract":"This study aimed to identify, assess, and summarize systematic reviews on dietary sodium intake restrictions for patients with heart failure. Literature searches were conducted on Pubmed, CINAHL, ScienceDirect, Cochrane Library, China National Knowledge Infrastructure, and the Wanfang Database up to January 2024. The methodological quality of the included reviews was assessed using the quality assessment tool from the Australian JBI Center for Evidence-Based Healthcare (2016). The results of systematic reviews and meta-analyses were synthesized and presented according to different outcome indicators. Nine systematic reviews were included in this study. The current evidence does not support the fact that dietary sodium intake restrictions for patients with heart failure have a positive impact on mortality rates, rehospitalization rates, and quality of life. Conversely, strict dietary sodium intake restrictions (≤ 2000 mg/day) may increase the risk of death, rehospitalization, and symptom exacerbation. Dietary sodium intake restriction may not have a positive impact on clinical outcomes in patients with heart failure. Nevertheless, more evidence is required to explore the differences in the impact of various levels of dietary sodium restriction on the outcomes and symptom management indicators of patients with heart failure.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction. GLP-1受体激动剂是有希望治疗射血分数保留型心力衰竭的抗炎药物。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-10-19 DOI: 10.1007/s10741-024-10450-6

Giovanni Battista Bonfioli, Luca Rodella, Marco Metra, Enrico Vizzardi

{"title":"GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction.","authors":"Giovanni Battista Bonfioli, Luca Rodella, Marco Metra, Enrico Vizzardi","doi":"10.1007/s10741-024-10450-6","DOIUrl":"https://doi.org/10.1007/s10741-024-10450-6","url":null,"abstract":"Heart Failure with Preserved Ejection Fraction (HFpEF) represents a significant challenge in modern cardiovascular medicine, characterized by diastolic dysfunction and a chronic pro-inflammatory milieu. The high prevalence of comorbidities such as diabetes, visceral obesity, and aging, which contribute to systemic inflammation, plays a pivotal role in the pathogenesis and progression of HFpEF. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs), a class of glucose-lowering drugs, have demonstrated a wide range of pleiotropic effects that extend beyond glycaemic control. These effects include the reduction of inflammation and oxidative stress, vasodilation, decreased arterial stiffness, and a reduction in myocardial fibrosis-key factors in the pathophysiology of HFpEF. Recent evidence from the STEP-HFpEF and STEP-HFpEF-DM trials provides the first robust data supporting the efficacy of GLP-1 RAs, specifically semaglutide, in improving the quality of life in obese patients with HFpEF. These trials also demonstrated a significant reduction in C-Reactive Protein (CRP) levels, reinforcing the hypothesis that suppressing the pro-inflammatory state may yield substantial clinical benefits in this patient population. These findings suggest that GLP-1 RAs could play a crucial role in the management of HFpEF, particularly in patients with obesity, by targeting the underlying inflammatory processes and contributing to better overall cardiovascular outcomes.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heart failure with reduced ejection fraction and chronic kidney disease: a focus on therapies and interventions. 射血分数降低型心力衰竭与慢性肾脏病：重点关注疗法和干预措施。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-10-18 DOI: 10.1007/s10741-024-10453-3

Hesham Salah Eldin Taha, Mohamed Momtaz, Ahmed Adel Elamragy, Omar Younis, Mera Alfred Sabet Fahim

{"title":"Heart failure with reduced ejection fraction and chronic kidney disease: a focus on therapies and interventions.","authors":"Hesham Salah Eldin Taha, Mohamed Momtaz, Ahmed Adel Elamragy, Omar Younis, Mera Alfred Sabet Fahim","doi":"10.1007/s10741-024-10453-3","DOIUrl":"https://doi.org/10.1007/s10741-024-10453-3","url":null,"abstract":"In heart failure with reduced ejection fraction (HFrEF), the presence of concomitant chronic kidney disease (CKD) predicts poorer cardiovascular outcomes, more aggravated heart failure (HF) status, and higher mortality. Physicians might be reluctant to initiate life-saving anti-HF medications out of fear of worsening renal function and a higher incidence of adverse events. Moreover, international guidelines do not give clear recommendations on managing this subgroup of patients as well as advanced CKD was always an exclusion criterion in most major HF trials. Nevertheless, in this review, we will highlight several recent clinical trials and post-hoc analyses of major trials that showed the safety and efficacy of the different therapies in HFrEF patients with CKD, besides several small-scale cohorts that tested guideline-directed medical therapies in End Stage Kidney Disease (ESKD). Regarding interventions in this subgroup of patients, we will provide up-to-date data on implantable cardioverter defibrillators, cardiac resynchronization therapy, and coronary revascularization, in addition to mitral valve transcatheter edge-to-edge repair and implantable pulmonary artery pressure sensors.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mineralocorticoid receptor antagonists and heart failure with preserved ejection fraction: current understanding and future prospects. 矿物皮质激素受体拮抗剂与射血分数保留型心力衰竭：当前认识与未来展望。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-10-17 DOI: 10.1007/s10741-024-10455-1

Xi Chen, Meinv Huang, Yi Chen, Haishan Xu, Meifang Wu

{"title":"Mineralocorticoid receptor antagonists and heart failure with preserved ejection fraction: current understanding and future prospects.","authors":"Xi Chen, Meinv Huang, Yi Chen, Haishan Xu, Meifang Wu","doi":"10.1007/s10741-024-10455-1","DOIUrl":"10.1007/s10741-024-10455-1","url":null,"abstract":"The mineralocorticoid receptor (MR), part of the steroid hormone receptor subfamily within nuclear hormone receptors, is found in the kidney and various non-epithelial tissues, including the heart and blood vessels. When improperly activated, it can contribute to heart failure processes such as cardiac hypertrophy, fibrosis, stiffening of arteries, inflammation, and oxidative stress. MR antagonists (MRAs) have shown clear clinical benefits in patients with heart failure with reduced ejection fraction (HFrEF). However, in cases of heart failure with preserved ejection fraction (HFpEF), there is considerable diversity due to its complex underlying mechanisms, resulting in conflicting findings regarding the effectiveness of MRAs in relevant studies. The concept of phenomapping presents an encouraging avenue for investigating different intervention targets and novel therapies for HFpEF. Post hoc analysis of the TOPCAT trial identified certain HFpEF phenotypes that responded favorably to spironolactone. Growing clinical and preclinical evidence suggests that non-steroidal MRAs, which exhibit greater receptor selectivity, stronger anti-fibrotic and anti-inflammatory properties, and fewer hormone-related side effects, may emerge as another promising treatment option for HFpEF alongside sodium-glucose co-transporter 2 (SGLT2) inhibitors. This review aims to outline the structural and functional characteristics of MR, discuss the physiological effects of its activation and inhibition, and delve into the potential for personalized MRA therapy based on the concept of HFpEF phenotype.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In-hospital initiation of sodium-glucose co-transporter-2 inhibitors in patients with acute heart failure. 急性心力衰竭患者在院内开始使用钠-葡萄糖协同转运体-2 抑制剂。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-10-15 DOI: 10.1007/s10741-024-10446-2

Muhammad Sameer Arshad, Adeena Jamil, Stephen J Greene, Harriette G C Van Spall, Gregg C Fonarow, Javed Butler, Muhammad Shahzeb Khan

{"title":"In-hospital initiation of sodium-glucose co-transporter-2 inhibitors in patients with acute heart failure.","authors":"Muhammad Sameer Arshad, Adeena Jamil, Stephen J Greene, Harriette G C Van Spall, Gregg C Fonarow, Javed Butler, Muhammad Shahzeb Khan","doi":"10.1007/s10741-024-10446-2","DOIUrl":"https://doi.org/10.1007/s10741-024-10446-2","url":null,"abstract":"Sodium-glucose cotransporter-2 (SGLT2) inhibitors provide cardiovascular and kidney benefits to patients with heart failure (HF) and/or chronic kidney disease (CKD), regardless of diabetes status and left ventricular ejection fraction (LVEF). Despite robust data demonstrating the efficacy of SGLT-2 inhibitors in both ambulatory and hospital settings, real-world evidence suggests slow and varied adoption of SGLT2 inhibitors among patients hospitalized for HF. Barriers to implementation of SGLT2i may include clinicians' concerns regarding potential adverse events such as diabetic ketoacidosis (DKA), volume depletion, and symptomatic hypoglycemia; or concerns regarding physiologically expected reductions in eGFR. Guidelines lack specific, practical safety data and definitive recommendations regarding in-hospital initiation and continuation of SGLT2i in patients hospitalized with HF. In this review, we discuss the safety of in-hospital SGLT2 inhibitor initiation based on recent trials and highlight the clinical implications of their early use in patients hospitalized for HF.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Harnessing the lymphatic system. 利用淋巴系统

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-10-15 DOI: 10.1007/s10741-024-10449-z

Barbara Ponikowska, Marat Fudim, Gracjan Iwanek, Robert Zymliński, Jan Biegus

{"title":"Harnessing the lymphatic system.","authors":"Barbara Ponikowska, Marat Fudim, Gracjan Iwanek, Robert Zymliński, Jan Biegus","doi":"10.1007/s10741-024-10449-z","DOIUrl":"https://doi.org/10.1007/s10741-024-10449-z","url":null,"abstract":"Heart failure (HF) is a growing concern, with significant implications for mortality, morbidity, and economic sustainability. Traditionally viewed primarily as a hemodynamic disorder, recent insights have redefined HF as a complex systemic syndrome, emphasizing the importance of understanding its multifaceted pathophysiology. Fluid overload and congestion are central features of HF, often leading to clinical deterioration and hospital admissions, with the role of the lymphatic system previously largely overlooked, partly due to diagnostic challenges and visualization difficulties. With the advancement of those techniques, pathophysiological changes occurring in the lymphatic system during HF, such as enlargement of the thoracic duct and the increased lymphatic flow, are now becoming apparent. This emerging research has begun to uncover the interplay between lymphatic dysfunction and HF, suggesting novel therapeutic targets. Advances in molecular biology, such as targeting vascular endothelial growth factor and promoting lymphangiogenesis, hold promise for improving lymphatic function and mitigating HF complications. This article provides a comprehensive overview of the evolving landscape of lymphatic system-targeted therapies for HF. It explores various intervention levels, from mechanical lymphatic decongestion to pharmaceutical interactions and lymphatic micro-circulation, offering insights into future directions and potential clinical implications for HF management.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The chronobiology of human heart failure: clinical implications and therapeutic opportunities. 人类心力衰竭的时间生物学：临床意义和治疗机会。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-10-11 DOI: 10.1007/s10741-024-10447-1

Francesco Gentile, Michele Emdin, Claudio Passino, Sabrina Montuoro, Paola Tognini, John S Floras, John O'Neill, Alberto Giannoni

引用次数: 0

Potential of plasma biomarkers for heart failure prediction, management, and prognosis: A multiomics perspective. 血浆生物标志物在心衰预测、管理和预后方面的潜力：多组学视角。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-10-08 DOI: 10.1007/s10741-024-10443-5

Erhou Zou, Xinjie Xu, Liang Chen

{"title":"Potential of plasma biomarkers for heart failure prediction, management, and prognosis: A multiomics perspective.","authors":"Erhou Zou, Xinjie Xu, Liang Chen","doi":"10.1007/s10741-024-10443-5","DOIUrl":"https://doi.org/10.1007/s10741-024-10443-5","url":null,"abstract":"Heart failure (HF) remains a major global health challenge, and more effective and comprehensive plasma biomarkers are needed to effectively treat HF patients. Multiomics studies have shown that DNA fragments, noncoding RNAs, proteins, and metabolites may be potential plasma biomarkers for HF. However, comprehensive reviews that focus on research on plasma biomarkers for HF from an omics perspective are lacking. This review summarizes the applications of various omics approaches in the exploration of biomarkers related to the risk assessment, diagnosis, subtype classification, medical management, and prognosis prediction of HF. Moreover, as heart transplantation and left ventricular assistant device (LVAD) implantation are terminal therapies for end-stage HF patients, this review also discusses the role of cell-free DNA as a biomarker for cardiac transplant rejection and omics studies of plasma biomarkers in patients who respond to LVAD therapy. Our findings suggest that future omics research on HF biomarkers should employ integrated multiomics methods and expand the sample size to increase the robustness of the results and that the identified biomarkers should be further validated in large cohorts.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142390064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pericardiotomy as a novel treatment for heart failure with preserved ejection fraction. 心包切开术是治疗射血分数保留型心力衰竭的一种新方法。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-10-08 DOI: 10.1007/s10741-024-10451-5

Shunichi Doi, Barry A Borlaug

引用次数: 0